Literature DB >> 24207092

Breast cancer laterality among Egyptian patients and its association with treatments and survival.

Ahmed A Zeeneldin1, Mohamed Ramadan, Nehal Elmashad, Ibrahim Fakhr, Amira Diaa, Ehab Mosaad.   

Abstract

BACKGROUND AND AIM: Breast cancers (BCs) involve the left side (LS) more than the right side (RS). Among the Egyptians, neither BC laterality nor its association with demographic factors, tumor locations, treatments and outcomes were previously reported. PATIENTS AND METHODS: Laterality was analyzed among 5459 BCs from the Gharbiah population-based cancer registry covering >5% of the Egyptian population. Cox proportional model was used to assess the independent effect of stage, ER, and laterality on overall survival (OS).
RESULTS: In Egypt, BCs involve LS more than RS with LS-to-RS ratio (LRR) of 1.16. LS predominance was evident among men and women and both younger (< 45 years) and older patients. HER2 over-expression and ductal cancers were significantly more in RSBCs while lobular cancers were significantly more in LSBCs. There were no significant differences in localization within the breast between LSBCs and RSBCs (p = 0.51). LS predominance was noticed across all subgroups except in patients with HER2 positive tumors (LRR = 0.63; p = 0.02). OS was significantly better in stage II and ER positive tumors than stage III and ER negative tumors. Despite OS of LSBCs being generally lower than RSBCs, this was not statistically significant. The significant impact of stage on OS was lost in LSBCs.
CONCLUSIONS: Among Egyptian patients, the left breast is at greater risk of cancer than the right one. Despite right-sided tumors seemed more aggressive, Left-sided ones tend to confer worse survival than right-sided tumors.
Copyright © 2013. Production and hosting by Elsevier B.V.

Entities:  

Keywords:  Breast cancer; Egypt; Laterality; Survival; Therapy

Mesh:

Year:  2013        PMID: 24207092     DOI: 10.1016/j.jnci.2013.09.003

Source DB:  PubMed          Journal:  J Egypt Natl Canc Inst        ISSN: 1110-0362


  6 in total

1.  A longitudinal study of the prevalence and characteristics of breast disorders detected by clinical breast examination during pregnancy and six months postpartum in Ibadan, Southwestern Nigeria.

Authors:  Stella O Odedina; IkeOluwapo O Ajayi; Adenike Adeniji-Sofoluwe; Imran O Morhason-Bello; Dezheng Huo; Olufunmilayo I Olopade; Oladosu A Ojengbede
Journal:  BMC Womens Health       Date:  2018-09-19       Impact factor: 2.809

2.  Serum Long Non-Coding RNAs PVT1, HOTAIR, and NEAT1 as Potential Biomarkers in Egyptian Women with Breast Cancer.

Authors:  Amal Ahmed Abd El-Fattah; Nermin Abdel Hamid Sadik; Olfat Gamil Shaker; Amal Mohamed Kamal; Nancy Nabil Shahin
Journal:  Biomolecules       Date:  2021-02-18

3.  Is laterality in breast Cancer still worth studying? Local experience in Bahrain.

Authors:  Suhair Al Saad; Hamdi Al Shenawi; Amer Almarabheh; Noor Al Shenawi; Abdulla Ismaeel Mohamed; Rami Yaghan
Journal:  BMC Cancer       Date:  2022-09-10       Impact factor: 4.638

4.  Clinicopathological features and prognosis associated with breast cancer laterality: a nationwide study from the Korean Breast Cancer Society.

Authors:  Bong Kyun Kim; Jung Eun Choi; Hyun Jo Youn; Hyung Seok Park; Dooreh Kim; Se Jeong Oh; Hyouk Jin Lee; Jina Lee; Woo Young Sun
Journal:  Ann Surg Treat Res       Date:  2022-09-06       Impact factor: 1.766

5.  Left sided breast cancer is associated with aggressive biology and worse outcomes than right sided breast cancer.

Authors:  Yara Abdou; Medhavi Gupta; Mariko Asaoka; Kristopher Attwood; Opyrchal Mateusz; Shipra Gandhi; Kazuaki Takabe
Journal:  Sci Rep       Date:  2022-08-04       Impact factor: 4.996

6.  Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran.

Authors:  Seied Asadollah Mousavi; Amir Kasaeian; Maziar Pourkasmaee; Ardeshir Ghavamzadeh; Kamran Alimoghaddam; Mohammad Vaezi; Hosein Kamranzadeh Fumani; Davoud Babakhani; Sahar Tavakoli
Journal:  PLoS One       Date:  2019-01-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.